Scopus BioPharma

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates consist of a combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company was founded on April 18, 2017 and is headquartered in New York, NY.

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment...

Scopus BioPharma Announces Appointment of Additional Directors

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of its initial public offering. The underwriters for the initial public offering exercised their over-allotment option in full. The company offered 575,000 shares of common stock,...

Scopus BioPharma Announces Closing of Initial Public Offering

Scopus BioPharma (SCPS) stock is soaring higher as the company's IPO continues on Thursday and InvestorPlace has all the details. The post SCPS Stock: 14 Things to Know About the Scopus BioPharma IPO appeared first on InvestorPlace.

SCPS Stock: 14 Things to Know About the Scopus BioPharma IPO

The stock price of Scopus BioPharma (NASDAQ: SCPS) increased from $8.17 at 11 AM ET on December 16 to $33.96 on December 17 at 4 PM ET. These are the details.

Scopus BioPharma Stock Price Surged Over 300% In Public Debut

Scopus Biopharma Inc (NASDAQ: SCPS) shares, which debuted on the Nasdaq Wednesday, are ripping higher. What Happened: New York-based Scopus, a biopharma company developing therapeutics for serious diseases with significant unmet needs, offered 500,000 shares through a Regulation A+ Tier 2 offering.

Newly Listed Scopus Biopharma Soars Over 500%: What Investors Need to Know

Oriental Culture Holding

Shares of Oriental Culture Holding Ltd. more than tripled (up 204.3%) in premarket trading Thursday, as the Hong Kong-based provider of collectibles and artwork e-commerce services heads for its third session as a public company.

Newly public Oriental Culture, Scopus BioPharma stocks more than triple ahead of the open

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the pricing of its initial public offering. The company's common stock is set to begin trading Wednesday, December 16, 2020 on the Nasdaq Global Market under the ticker symbol "SCPS". The company...

Scopus BioPharma Announces Pricing of Initial Public Offering

News for Scopus BioPharma Stock (SCPS)